Balchem (BL9B) Stock Overview
Develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BL9B from our risk checks.
BL9B Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
An Undervalued 3.3Moz Gold Project in Canada
Key takeaways Upside Gold is developing the Kena Gold Project, near the town of Nelson in the Kootenays region of southern British Columbia. Kena hosts a historical gold resource of 3.33 million ounces (561,000 ounces Indicated and 2.77 million ounces Inferred) across a 10,200-hectare land package.Read more
Balchem Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$144.00 |
| 52 Week High | US$154.80 |
| 52 Week Low | US$118.60 |
| Beta | 0.95 |
| 1 Month Change | 1.69% |
| 3 Month Change | 4.42% |
| 1 Year Change | 3.15% |
| 3 Year Change | 24.35% |
| 5 Year Change | 42.15% |
| Change since IPO | 571.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| BL9B | DE Chemicals | DE Market | |
|---|---|---|---|
| 7D | 1.3% | 0.9% | 0.5% |
| 1Y | 3.2% | 8.7% | 8.5% |
Return vs Industry: BL9B underperformed the German Chemicals industry which returned 9.1% over the past year.
Return vs Market: BL9B underperformed the German Market which returned 8.4% over the past year.
Price Volatility
| BL9B volatility | |
|---|---|
| BL9B Average Weekly Movement | 3.8% |
| Chemicals Industry Average Movement | 5.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in DE Market | 14.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: BL9B has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BL9B's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 1,352 | Ted Harris | www.balchem.com |
Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry.
Balchem Corporation Fundamentals Summary
| BL9B fundamental statistics | |
|---|---|
| Market cap | €4.76b |
| Earnings (TTM) | €131.20m |
| Revenue (TTM) | €878.79m |
Is BL9B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BL9B income statement (TTM) | |
|---|---|
| Revenue | US$1.04b |
| Cost of Revenue | US$666.53m |
| Gross Profit | US$370.63m |
| Other Expenses | US$215.79m |
| Earnings | US$154.85m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.84 |
| Gross Margin | 35.74% |
| Net Profit Margin | 14.93% |
| Debt/Equity Ratio | 13.0% |
How did BL9B perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/15 13:30 |
| End of Day Share Price | 2026/04/15 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Balchem Corporation is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Labick | CJS Securities, Inc. |
| Timothy Ramey | D.A. Davidson & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |